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Proliferation  is  an  important  part  of cancer  development  and  progression.  This  is manifest  by altered
expression  and/or  activity  of  cell cycle  related  proteins.  Constitutive  activation  of many signal  trans-
duction  pathways  also  stimulates  cell  growth.  Early  steps  in  tumor  development  are  associated  with  a
ﬁbrogenic  response  and  the  development  of a hypoxic  environment  which  favors  the  survival  and  prolif-
eration  of cancer  stem  cells.  Part  of  the  survival  strategy  of  cancer  stem  cells  may  manifested  by  alterations
in cell  metabolism.  Once  tumors  appear,  growth  and  metastasis  may  be  supported  by overproduction
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Therapeutic targets
Cancer stem cells
Cancer hallmarks
of appropriate  hormones  (in  hormonally  dependent  cancers),  by promoting  angiogenesis,  by undergo-
ing epithelial  to  mesenchymal  transition,  by  triggering  autophagy,  and  by taking  cues  from  surrounding
stromal  cells.  A number  of  natural  compounds  (e.g.,  curcumin,  resveratrol,  indole-3-carbinol,  brassinin,
sulforaphane,  epigallocatechin-3-gallate,  genistein,  ellagitannins,  lycopene  and  quercetin)  have  been
found  to inhibit  one  or  more  pathways  that  contribute  to proliferation  (e.g.,  hypoxia  inducible  factor
1, nuclear  factor  kappa  B, phosphoinositide  3 kinase/Akt,  insulin-like  growth  factor  receptor  1,  Wnt,  cell
cycle  associated  proteins,  as  well  as androgen  and  estrogen  receptor  signaling).  These  data,  in combination
with bioinformatics  analyses,  will be very  important  for  identifying  signaling  pathways  and molecular
targets  that  may  provide  early  diagnostic  markers  and/or  critical  targets  for the  development  of new
drugs or  drug  combinations  that block  tumor  formation  and  progression.
evier  Ltd.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Factors in cell survival and proliferation the contribute to carcinogenesis.
Factor Contribution to carcinogenesis
EMT  Promotes stem cell growth, metastasis
Hypoxia HIFs promote proliferation of CSCs and
angiogenesis; alters metabolism;
constitutive activation of signaling
pathways
Autophagy Promotes cell survival in response
dysregulated signaling-mediated
proliferation, enhanced glycolysis, and
hypoxia
CSCs Dysregulation in “stemness,” quiescence,
self-renewal, the ability to produce
differentiated progeny, resistance to
apoptosis, and chemoresistance, resulting
in  altered cell fate and unregulated cell
growth
Cell cycle proteins Dysregulated expression of cell cycle
proteins (Rb, CDKs, cdk inhibitors)
promote uncontrolled cell proliferation
Signal transduction pathways Constitutive activation of multiple
signaling pathways promote uncontrolled
proliferation (e.g., Wnt, Notch, IGF,
PI3K/Akt, NF-B, Hh)
Altered cell metabolism Promotes altered survival and growth in
the  adverse conditions (e.g., hypoxia) in
early stages of carcinogenesis (e.g., altered
glycolysis and methionine metabolism)
Hormone signaling Promote the growth of hormone
responsive cancers through constitutive
activation of estrogen and androgen
signaling pathways
When EMT  occurs in adult tissues in response to injury or during
tumorigenesis, epithelial cells change morphological appearance,© 2015  Els
. The centrality of cell proliferation as a target in
arcinogenesis
The cancer cell embodies characteristics that permit survival
eyond its normal life span and to proliferate abnormally. Cancer
herapy, involving cytotoxic drugs, kills cells that have a high basal
evel of proliferation and regeneration. While this type of therapy
argets tumor cells, it affects rapidly proliferating, nontumor cells in
he skin, hair, and epithelium of the gastrointestinal tract, account-
ng for the high level of toxicity associated with such treatments.
rowth of normal tissue is tightly regulated while this regulation
s lost in tumor cells. Lack of normal growth control is not only
perative in early tumorigenesis but also during tumor metastasis.
hus, there is much to be learned from studies that address how and
hen abnormal growth begins, and then to use this knowledge to
dentify novel therapeutic targets and approaches that would more
peciﬁcally treat cancer cells without damaging the normal host
ells.
Carcinogenesis is a multistep process in which changes in tissue
rchitecture and the formation of preneoplastic nodules precede
he appearance of cancer. These alterations are associated with
hanges in cell phenotype that include epithelial to mesenchymal
ransition (EMT) and cell migration, resulting in local regions of
ypoxia that promote the survival and growth of tissue stem cells
1–5], as well as angiogenesis [6–9] (Table 1). Autophagy also pro-
otes the survival of preneoplastic and tumor cells under stressful
onditions. While the growth and survival of normal cells are under
artial control from growth factors and hormones, alterations in
ignaling pathways, resulting from mutations and/or epigenetic
hanges, renders cells resistant and independent of these pathways.
uch changes promote survival and growth both by constitu-
ively stimulating pathways that favor proliferation [10], and by
nhibiting and/or overriding apoptotic pathways. Initially, altered
ignaling pathways, as well as changes in the metabolomics proﬁle,
pigenetically modify the patterns of gene expression in the cell,
nd as such are therapeutically reversible (Table 1). In contrast,
umor progression proceeds by “driver” mutations that are more
ifﬁcult to target pharmacologically. Thus, elucidation of the under-
ying epigenetic mechanisms responsible for these alterations will
rovide meaningful targets for the development of novel therapeu-
ics prior to or at the earliest stages of malignant transformation.
To facilitate a better understanding of the early changes seen
n carcinogenesis, this review presents discussion of the major
athways, disruption of which promote unregulated proliferation
f cancer cells. This review focuses on changes in tissue archi-
ecture (EMT and migration), formation of preneoplastic nodules,
evelopment of hypoxia, survival and growth of cancer stem cells,
utophagy and growth factor independent proliferation (Table 1).
ach section attempts to identify the “best” molecular targets (e.g.,
eceptors, signaling molecules, etc.) that might be exploited thera-
eutically. The “best” targets were chosen based upon their altered
xpression/function that promoted proliferation in many different
uman cancers. Additional questions include: Does loss of a targetTumor microenvironment Stromal-tumor cell crosstalk promotes
growth and metastasis of cancer stem cells
prevent tumor initiation or block tumor maintenance? What is the
effect of global loss of a target in other tissues? Will there be off
target effects due to additional functions and/or because of a high
degree of homology with other proteins? Many of these targets are
pleotropic, regulating different pathways and as such their target-
ing might abrogate additional required hallmarks. At the end of this
review, there is a discussion of natural products that are likely to be
effective against these molecular targets and pathways, which may
be useful in delaying the onset of cancer and/or reversing cancer
cell proliferation, with reduced associated toxicity. Many natural
products have much lower toxicity than compounds or deriva-
tives obtained from chemical libraries, suggesting that their further
development could provide distinct advantages.
2. How does EMT  contribute to tumor proliferation?from an ordered structure with apical and basal polarity to a less
ordered, migratory ﬁbroblastic shape. The Snail family of transcrip-
tion factors (Snail1/Snail and Snail2/Slug) is closely associated with
M.A. Feitelson et al. / Seminars in Can
Fig. 1. Senescence-resistant stem cells (SCs) are targets of Snail induced tumors.
Tumor-associated Snail1/2 contribute to metastasis, but are also involved in early
stages of cancer. In this model, cells expressing oncogenic Snail1/2 undergo EMT
or  senescence. However, SCs are resistant to this fate. Snail1/2 increases resistance
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whereby cells degrade macromolecules and organelles, and theno  DNA damage, allowing those cells to accumulate mutations that fuel malignant
ransformation and uncontrolled cell growth.
MT [11], because they suppress epithelial cadherin (E-cadherin)
xpression [12–14], which normally facilitates cell–cell interac-
ions, providing polarity cues and preventing dissemination. Snail
ssociated EMT  is normally under stringent regulation [15–17], but
hen that is lost, cancer may  appear [17–19]. Increased expres-
ion of Snail and Slug protects cells from death induced by the
oss of survival factors or by apoptotic stimuli [15,20–24]. Ele-
ated Snail1/2 results in increased protection from DNA damage
17,20,21], increased resistance to chemotherapeutic agents [25]
nd radiation therapy. Snail and Slug may  also affect a cell’s
esponse to genotoxic stress, increasing DNA damage, which then
ay  contribute to cancer development (Fig. 1).
Snail1 induced E-cadherin depletion is associated with the
cquisition of invasive properties in several epithelial cell lines
12,26–29] and in tumors [18,19]. Snail expression also correlates
ith poor survival in human cancer [30–33]. Cells expressing
nail1 typically have an undifferentiated phenotype [18], sug-
esting a potential role in “stemness” and the genesis of cancer
tem cells (CSC) (described below). CSCs are resistant to cell cycle
rrest or senescence thereby accumulating oncogene induced
NA damage and mutations that guide malignant transformation.
ells undergoing EMT, and cells with properties of CSCs are
esistant to typical cancer intervention strategies, tumor relapse
ollowing therapy, and metastasis. However, the expression of
elected microRNAs (miRNA) that regulate gene expression in
hese cells can be altered by natural products, such as curcumincer Biology 35 (2015) S25–S54 S27
and epigallocatechin-3-gallate (EGCG) [34] (see below), suggesting
a fresh therapeutic approach that needs to be developed in the
future. EMT  may  occur prior to tumor appearance, resulting in
aberrant tissue architecture and the development of hypoxia. In
addition, CSCs drive tumor formation. These events further suggest
the importance of these targets in cancer chemoprevention.
3. How does hypoxia contribute to tumor proliferation?
3.1. Hypoxia inducible factors [HIFs]
Cancer development results from the selection of cells with
mutation(s) that provide survival and proliferative advantages.
Normal barriers to proliferation are overcome as clones adapt
to an ever changing hostile microenvironment, where low oxy-
gen tension, low glucose levels, and an acidic extracellular pH
(all of which increase genetic instability) are found. The hypoxia
inducible factors, HIF-1 and HIF-2, are upregulated in response
to these conditions. This could occur by constitutive activation of
PI3K signaling or inactivating mutations in, for example, the von
Hippel–Lindau tumor suppressor, VHL [35–37], which normally
deacetylates HIF-1, leading to HIF-1 polyubiquitination and pro-
teasomal degradation [38]. HIFs trans activate genes mediating
proliferation, angiogenesis, intermediate metabolism (glycolysis)
and pH regulation, which promote tumor development [39].
HIF-1 stimulates production of growth factors, such as
transforming growth factor  (TGF-),  insulin-like growth fac-
tor 2, interleukin-6 (IL-6), interleukin-8, macrophage migration
inhibitory factor (MIF), and growth factor receptors, such as the
epidermal growth factor receptor (EGFR), resulting in continuous
proliferative signaling. In the hypoxic environment, constitutive
activation of these signaling pathways (e.g., Ras [1] and PI3K [2])
stabilizes HIF-1 and may  result in “oncogene addiction” that per-
sists through the transition from adenoma to carcinoma. In the
case of PI3K, constitutive activation may  result from the appear-
ance of mutations in tumor suppressor genes (e.g., the phosphatase
and tensin homolog [PTEN]), from activating mutations in the
PI3K complex itself, or from aberrant signaling in receptor tyro-
sine kinases [40]. Elevated PI3K stimulates the mechanistic target
of rapamycin (mTOR) [35], and ATP production [41,42], both of
which support cell proliferation. Strategies to block the prolifer-
ative effects of hypoxia include the design of small molecule HIF
inhibitors, by enhanced degradation of HIF-1 via inhibition of heat
shock protein 90 (Hsp90), or by inhibiting mTOR [43].
The Warburg effect describes the ability of tumor cells to switch
from oxidative phosphorylation to glycolytic metabolism as their
primary energy source. HIF-1 increases the expression of glycolytic
enzymes and glucose transporters 1 and 3 [1], which facilitate glu-
cose uptake necessitated by inefﬁcient glycolysis. HIF-1 channels
glucose toward glycolysis, and represses mitochondrial respira-
tion, protecting cells from oxidative damage. Increased glycolytic
metabolism promotes ATP production to sustain cell proliferation
in the absence of oxygen. The development of glycolytic inhibitors
has shown promising results in vitro [43]. Energy depletion and
hypoxia also suppress mTOR signaling through activation of Ataxia
telangiectasia mutated (ATM, involved in cell cycle arrest and DNA
repair), saving on energy consuming protein synthesis and DNA
damage responses. Thus, ATM or checkpoint 1 inhibitors may also
abrogate metabolic adaptation of cells to hypoxia and subsequent
survival [6,43].
HIF-1 also promotes autophagy, which is a mechanismreutilize the products for energy production and biosynthesis,
thereby promoting cell survival. Thus, blocking autophagy via inhi-
bition of IRE1 (a serine/threonine protein kinase/endoribonuclease
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hat alters host cell gene expression under ER stress) may  increase
he sensitivity of cells to apoptosis in hypoxic environments [43].
levated HIF-1 levels may  also increase de novo fatty acid synthesis
44,45] by upregulation of fatty acid synthase (FAS) transcription.
his is mediated through sterol regulatory element binding protein
 via Akt1 activation. Thus, inhibition of FAS or HIF-1 might block
atty acid synthesis mediated growth as well.
Despite the acidic pH due to accumulation of lactic acid during
ypoxia, intracellular pH is maintained near neutral as a result of
IF-mediated up regulation/activation of membrane located trans-
orters, exchangers, pumps and ectoenzymes. These include the
miloride sensitive Na+/H+ Exchanger, the H+/lactate cotransporter
monocarboxylate transporter, MCT4), and carbonic anhydrase
CA) IX and XII [6]. Although speciﬁc inhibitors of MCT4 are not
vailable, disrupting pH homeostasis is justiﬁed by the antitu-
or  and antimetastatic activity of CA inhibitors in xenografts
43]. Bioreductive agents may  also be therapeutically useful as
ong as strategies are applied to increase their extravascular
enetration [45]. Thus, while HIF-1/2 up regulation is a natural cel-
ular response to hypoxia, this epigenetically fuels pathways that
romote proliferation, creating an environment where mutation
ecomes more likely. Blocking hypoxia is attractive because it rep-
esents a predriver mutation state, where reversibility may  be more
easible.
.2. How does hypoxia promote growth in preneoplastic tissues?
Premalignant nodules are mostly devoid of blood vessels which
imits the diffusion of substrates across the basement membrane
rom the local blood supply. Adaptation to these conditions is crit-
cal in the transition from a benign nodule to malignancy. As such,
arcinoma in situ (CIS) becomes malignant following rupture of
he basement membrane and invasion into the surrounding tissue,
hich may  be facilitated by increased acid production [7]. Hypoxia
ay  promote CIS progression by selecting for cells that are resis-
ant to extracellular acidosis and those with upregulated glycolysis.
hus, the transition from preinvasive to invasive tumor may  be
losely linked to the CIS microenvironment [7,8].
In inﬂammation related carcinogenesis, altered tissue archi-
ecture due to necrosis and the development of hypoxia attracts
nﬂammatory responses [46]. The latter usually includes tumor
ssociated macrophages (TAM) that stimulate tumor prolifera-
ion (by promoting angiogenesis) and progression (by promoting
nvasion and metastasis) through the secretion of growth factors
nd cytokines [47,48]. HIF-1  is activated by these proinﬂamma-
ory cytokines, which include tumor necrosis factor alpha (TNF-)
nd interleukin-1  (IL-1). Proinﬂammatory cyclooxygenase 2
COX2) also mediates IL-1-induced HIF-1 expression through
roduction of prostaglandin E2 (PGE2). This leads to activation of
he ras-mitogen activated protein kinase (MAPK) pathway, which
aintains the prosurvival COX2/PGE2 pathway. Src is another
ey factor in hypoxia induced vascular endothelial growth factor
VEGF) and PGE2-mediated transactivation of EGFR. In addition,
-catenin-HIF-1 interaction results in the enhancement of HIF-1
ranscriptional activity [8,49]. Importantly, HIF-1 is also activated
n TAMs under hypoxic conditions [50,51], resulting in the stimu-
ation of nuclear factor kappa B (NF-B), and further inﬂammatory
ytokine production, including sustained elevations in HIF-1. This
eedback promotes tumor progression [52]. Thus, HIFs link hypoxia,
hronic inﬂammation, and tumor progression by reprogramming
umor cells, macrophages and other cells during cancer devel-
pment. Therefore, introducing natural compounds that target
ypoxia in general, and NF-B in particular, might delay or prevent
he onset of dysplasia or/and neoplastic transformation, particu-
arly in cell types where HIF promotes early steps of carcinogenesis.
n this context, the antiinﬂammatory properties of many naturalcer Biology 35 (2015) S25–S54
compounds may  be able to attenuate the induction of HIF-1 (see
below), thereby potentially preventing tumor development.
4. Autophagy and tumor cell proliferation
In normal cells, basal autophagy is a mechanism that maintains
cellular homeostasis by removing protein aggregates and dam-
aged organelles, whereas starvation induced autophagy prolongs
cell survival by recycling amino acids and energy, which are both
important for cellular ﬁtness and preserving viability [53,54]. The
basal level of autophagy increases in cancer cells to withstand
stresses due to dysregulated signaling mediated proliferation [55],
enhanced glycolysis [56], hypoxia [57], and to maintain cancer cells
in a state of quiescence [58]. However, autophagy can promote
tumor cell survival [59] or cell death [60] depending upon the
tumor type, and thus, the implications of induced autophagy are
not completely understood. It can be modulated therapeutically,
either promoting survival or death [61,62].
4.1. Autophagy inducers
mTOR, which is part of a larger mechanistic target of rapamycin
complex 1 (mTORC1), normally inhibits autophagy. When mTOR
is inhibited by stress signals (e.g., HIF, dysregulated PI3K/Akt
and elevated p53) [63,64], the Beclin 1/class III PI3K complex
is activated [65], which promotes autophagy [66]. Alternatively,
antiapoptotic B cell leukemia/lymphoma-2 (Bcl-2) family pro-
teins, overexpressed in multiple tumor types, inhibit apoptosis and
autophagy [67], suggesting that small molecule antagonists of Bcl-2
and related molecules (e.g., Bcl-2 larger isoform, Bcl-XL), known as
BH3 mimetics (ABT-737/263, obatoclax), can competitively disrupt
the Beclin 1-Bcl-2/Bcl-xL interaction to trigger autophagy [67] and
apoptosis. A variety of mTORC1 inhibitors have been considered as
antitumor agents that block proliferation. These include rapamycin,
temsirolimus, deforolimus, metformin [68,69], the dual PI3K-mTOR
inhibitors NVP-BEZ235 [70] and PI-103 [71], as well as combi-
nations of these and other agents that induce autophagy [72,73]
(Fig. 2). Interestingly, several polyphenolic compounds, such as
resveratrol [74], curcumin [75], rottlerin, genistein, and quercetin
[76], were reported to induce autophagy and cancer cell death, sug-
gesting that these compounds may  be clinically valuable in cancer
treatment and/or chemoprevention.
4.2. Autophagy inhibitors
Knockdown of genes mediating autophagy [77,78] may con-
tribute to tumor regression, as has been seen in human pancreatic
cancer [79]. Human cancer cell lines harboring activating muta-
tions in H-ras or K-ras have high basal levels of autophagy that
promotes survival. Inhibition of autophagy in these lines reduces
tumorigenicity [79,80]. Inhibition of autophagy also sensitizes
tumor cells to alkylating agents and cetuximab [81]. In apopto-
sis defective leukemic and colon cancer cell lines, inhibition of
autophagy sensitized resistant cells to TNF related apoptosis induc-
ing ligand (TRAIL)-mediated apoptosis [82]. The natural compound,
matrine, is a novel autophagy inhibitor that modulates the matura-
tion of lysosomal proteases [82]. Combination therapies involving
drugs that modulate autophagy are being classiﬁed as early or
late stage inhibitors. Early inhibitors include 3-methyladenine,
wortmannin and LY294022, which target the class III PI3K [83].
Late stage inhibitors include the antimalarial drugs baﬁlomycin
A1 (which targets a vacuolar adenosine triphosphatase) [84], as
well as monensin and chloroquine, both of which prevent the acid-
iﬁcation of lysosomes [85]. Microtubule disrupting agents (e.g.,
taxanes, nocodizole, colchicine and vinca alkaloids) inhibit fusion
of autophagosomes to lysosomes, thereby preventing steps in
M.A. Feitelson et al. / Seminars in Cancer Biology 35 (2015) S25–S54 S29
Fig. 2. Major pathways of autophagy and natural compounds that inhibit these pathways. Autophagy inducers such as starvation (which may occur during hypoxic conditions)
modulate the activity of the phagophore, consisting of the Atg1/unc-51-like kinase (ULK) complex, Beclin 1/PI3K complex, ubiquitin-like proteins (several Atg proteins), and
proteins that mediate fusion between autophagosomes and lysosomes. Phagophore formation could be blocked with PI3K inhibitors. Autophagy induction involves budding
of  autophagosomes from the ER membranes, and inhibits interaction of TORC1 with the ULK1/2 complex. The latter regulates the activity of Beclin 1/class III PI3K complex.
Beclin  1 interacts with factors that modulate its binding to Vps34, the catalytic unit of the PI3K, whose lipid kinase activity is essential for autophagy. This step could also be
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aharmacologically blocked. Fully mature autophagosomes can fuse with endosome
ith  those from acidic lysosomes to acquire hydrolytic activity, degrade their cargo
lso  be inhibited by a variety of compounds, suggesting that autophagy would be a
he formation of vacuoles that mediate autophagy. In addition,
lomipramine (an anti-depressant) and lucanthone (an antischis-
ome drug) block autophagosome degradation [86,87], suggesting
ew indications for existing drugs (Fig. 2). These observations imply
hat the modulation of autophagy may  be an important therapeutic
arget in ﬁghting cancer.
Similar to hypoxia, autophagy represents a viable way to treat
ancer independent of targeting individual driver mutations. How-
ver, the main issue is that blocking or inducing autophagy appears
o have opposite effects in different tumor types. Thus, markers to
ndicate which outcome would result must be identiﬁed before this
ine of targeting can be considered. Recently, a number of natu-
al products were shown to be modulators of autophagy, such as
aﬁlomycin A1 [88,89], feroniellin A [90] and oblongifolin C [91].
. Survival and growth of cancer stem cells (CSCs)
.1. Distinguishing features of adult and cancer stem cells
Stem cells (SCs) and CSCs share similar characteristics of “stem-
ess,” quiescence, self renewal, the ability to produce differentiated
rogeny, resistance to apoptosis, and chemoresistance [92–103].
hat distinguishes CSCs from adult SCs is the aberrant regula-
ion of these processes in the former, resulting in altered cell fate
nd unregulated cell growth [94]. Aberrant Hedgehog (Hh), Notch
nd Wnt  pathways, either through overexpression of wild typerm amphisomes. Autophagosomes or amphisomes fuse their external membranes
ecycle essential biomolecules to the cytoplasm. Both fusion and degradation could
 target in early stages of carcinogenesis [689].
signaling molecules, or by activating mutations in these signaling
pathways, contribute to the malignant conversion of adult stem
cells to CSCs [103]. Further, the PTEN tumor suppressor maintains
adult stem cells in quiescence, while in CSCs, PTEN is often mutated
or deleted, resulting in increased expression of genes that promote
the cell cycle and DNA replication.
The tumor mass contains a small proportion of CSCs that initi-
ate/maintain malignant growth and differentiated progeny of these
CSCs that do not [104,105]. Adult SCs divide asymmetrically, giv-
ing rise to a differentiated daughter cell and progenitor cell capable
of a limited number of additional cell divisions [106]. In contrast,
CSCs divide symmetrically into progenitor cells that possess an
unlimited replicative potential that allows them to undergo an
indeﬁnite number of cell divisions. The latter may  explain tumor
relapse after initial therapy, where most of mature tumor cells are
eliminated, while therapy resistant CSCs become reactivated and
proliferate. Initial tumor responses might mean little if CSCs deter-
mine outcome [107], suggesting that CSCs are the cells that must
be effectively targeted to achieve a deﬁnitive cure [107,108].
5.2. Stem cells and cancer initiationSince the pathogenesis of cancer involves the appearance of
driver mutations in long lived adult SC [109], only cells with self
renewal capacity, especially in tissues with high cellular turnover
(e.g., skin, intestine [109], breast [110–112] and hematopoietic cells
S30 M.A. Feitelson et al. / Seminars in Cancer Biology 35 (2015) S25–S54
Fig. 3. Cancer stem cells (CSCs) arise from tissue speciﬁc stem or progenitor cells that have undergone changes in gene expression (reprogramming) as a result of epige-
netic  mechanisms and/or oncogenic mutations. These CSCs undergo proliferation and differentiation into tumor cells. Standard therapeutic approaches target mostly the
differentiated tumor cells, which reduce the bulk of the tumor, but CSCs are resistant to most therapies that are effective against the bulk of the tumor cells. In this model of
carcinogenesis, it will be important to target key alterations in gene expression that drive reprogramming, be they natural compounds that epigenetically downregulate the
expression of genes that contribute to reprogramming, and/or drugs that are effective against molecules that acquire driver mutations. Thus, blocking the reprogramming
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cnd  proliferation of stem cells is likely to contribute importantly to cancer chemop
104,113]), should be most susceptible to malignant transforma-
ion. In chronic myelogenous leukemia (CML) [90], for example, the
reakpoint cluster region/Abelson (Bcr-Abl) translocation appears
t the beginning of the hematopoietic differentiation tree [114],
mplying an intimate relationship between SC, mutation, and tumor
evelopment. In some cancers, germline mutations in tissue SC
e.g., in colon cancer and medulloblastoma) also suggest a central
ole for these cells in tumor pathogenesis [115,116]. In other cancer
ypes, including solid tumors [117,118], dedifferentiation and the
eacquisition of the stem-like phenotype in mature cells may  also
e involved (e.g., observed in the pathogenesis of melanoma, breast
nd pancreatic cancers) [119–122]. This will inﬂuence the choice
f cell target and the timing at which therapeutic intervention will
ave the greatest impact. However, phenotypic plasticity in tumors
ay preclude a simple approach to therapeutic intervention, since
elected cell types in a tissue may  have acquired the “stemness”
henotype in a given microenvironment.
Constitutively expressed oncogenes also contribute to cancer
evelopment, not just by inducing proliferation, but also because
f their capacity to reprogram the epigenome of the target cell
123]. Reprogramming of differentiated cells can be achieved by the
ransient expression of the transcription factors octamer binding
ranscription factor 4 (Oct4), Kruppel-like factor 4, Nanog, and myc
hat “reset” the epigenetic status of cells and allow them to adopt
 plethora of fates, including extended proliferation [123] (Fig. 3).
f CSCs arise through a reprogramming like mechanism, then early
ntervention that target CSCs may  be critical for the development
nd success of therapeutics.
.3. What regulates quiescence in stem cells?
If stem cell activation is important to the pathogenesis of cancer,
aintaining stem cell quiescence and inhibiting their proliferation
ay  have therapeutic value. This may  prevent or delay the onset of
rimary tumors (e.g., in CML, melanoma, breast cancer, non small
ell lung cancer, and osteosarcoma) [124–128], and help to prevent
etastasis or relapse [129,130]. Micrometastases are quiescent forengthy periods, and during this time, are resistant to most ther-
peutic approaches that target cell proliferation. This is why  it is
mportant to understand dormancy and growth regulation in stem
ells.ion.
Quiescence is most likely controlled by a combination of cell
intrinsic and cell extrinsic (niche) interactions. The intracellular
or “cell intrinsic” signals resemble normal processes that control
cell cycle progression and survival. Thus, therapies that target G1
regulators (such as cyclin D), cyclin dependent kinase 4 (cdk4) or
p27, or apoptotic regulators (such as Bcl-2), might be effective.
Two canonical developmental pathways, Wnt/-catenin and Hh,
appear important in the self renewing potential of CSC [131,132].
Wnt  and Hh are generally inactive in somatic adult cells, but are
reactivated in adult SCs and CSC. The metastasis suppressor gene,
mitogen activated protein kinase kinase 4, is part of a growing
lists of genes that block proliferation through the activation of
MAPK p38 [133–135], suggesting they may  become therapeutic
targets.
On the cell extrinsic side, the chemokine ligand 12 (CXC-12)
and corresponding receptor (CXCR-4) interaction is required for
breast, prostate, and multiple myeloma (MM)  CSC colonization and
subsequent quiescence [136]. In CML  and MM,  CSC can be mobilized
from quiescence into the cell cycle by the addition of granulocyte
colony stimulating factor (G-CSF), which degrades CXCL-12, or by
an antagonist of CXCR-4 [137]. In the clinic, however, G-CSF has had
mixed results, since it impacts both CSCs and adult SCs [137]. Thus,
caution must be applied, as therapies should not affect or deplete
adult SCs.
As the CSC fate decision is most likely controlled epigeneti-
cally, various transcription factors have been implicated in these
processes. For example, CCAAT/enhancer binding protein alpha
(C/EBP) appears to regulate myeloid differentiation and self
renewal of fetal liver hepatic SCs. Myeloid Elf-1-like factor is a
transcriptional activator [138,139] that promotes the G1- to S-
phase transition and enhances the movement of hepatic SCs out
of a quiescent state (Go-phase) into the cell cycle [140,141]. The
proangiogenic factor, angiopoietin-1, inactivates glycogen syn-
thase kinase 3 (GSK3)  via phosphorylation, thereby releasing
active -catenin, which then migrates to the nucleus and upreg-
ulates the expression of genes that promote cell survival (by
blocking apoptosis) and cell proliferation [142]. However, caution
must be exercised in pursuing any of these as putative ther-
apeutic targets, since the development of corresponding drugs
would probably be associated with the appearance of considerable
toxicity.
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Fig. 4. Selected natural products that block cell cycle progression. Receptor activation, via Raf, MEK, ERK, and AP1, increases cyclin D1 transcription. Cyclin D1 binds to cdk4
and  the assembly factor, p27Kip1 to create an active ternary complex. This complex can be inactivated by association with Ink4A or loss of cyclin D1 via GSK-3-mediated
proteasomal degradation. Active cyclin D-cdk4-p27 complexes phosphorylate (inactivate) Rb, causing limited transcriptional activation of cyclin E. Increased cyclin E levels
shifts  the balance of inactive cyclin E-cdk2 complexes to active cyclin E-cdk2 complexes, which in turn phosphorylates its associated p27, targeting it for proteasomal
degradation. p27-free cyclin E-cdk2 complexes now fully phosphorylate Rb, causing S phase gene transcription, and progression into S phase, where the cell cycle proceeds
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independently of extracellular signals. As shown in red, many natural compounds c
r  cyclin E. Some of these acts via altered expression of microRNAs.
odiﬁed from reference [634].
. Targeting cell cycle proteins in sustained proliferative
ignaling
Cell cycle progression is controlled by cyclin-cdk complexes,
hat include cdk interacting protein p21CIP1, kinase inhibitory pro-
eins (Kips) (p27KIP1, p57KIP2), and INhibitors of CDK4 (INK4s:
16INK4a, p15INK4b, p18INK4c, p19INK4d), which activate and inhibit
hese complexes, respectively [143]. The G1 phase of the cell cycle
s the only time that a cell can respond to extracellular cues, and
rogression depends on the balance of proliferative and antiprolif-
rative signals. In the presence of “go” signals, progression into S
hase occurs; in the presence of “stop” signals, the cell arrests in G1.
hus, cancer can be thought of as a disease of the cell cycle: where a
ancer cell ignores the “stop” signals and does not wait for the “go”
ignals. The result is excessive DNA replication, which increases the
ikelihood of replication induced mutations and telomere degener-
tion, further disabling other hallmark pathways.
.1. Retinoblastoma (Rb) pathway
The Rb pathway (INK4-cyclin D-cdk4/6-Rb), which controls the
1-S phase transition, is universally disrupted in human cancer.
yclin D-cdk4/6 complexes initiate G1 progression by phosphory-
ating (inactivating) Rb, thus relieving transcriptional repression
y the Rb-E2F complex (Fig. 4). Following Rb phosphorylation, E2F
s released, inducing transcription of genes necessary for S-phase
ntry. Although Rb loss occurs in some tumor types, most can-
ers retain wild type Rb, and instead have mutated or activated
ell cycle proteins that regulate Rb. In other tumor types, cell cycle
roteins downstream of oncogenic pathways are frequently altered
osttranslationally, demonstrating that these represent targets in
ancer therapy [144]..2. Cyclins D and E
The gene encoding cyclin D is the second most ampliﬁed locus
n human cancer, and is directly downstream from many oncogenic1 arrest in several cancer cell culture models, due to effects on cyclin D1, p21, p27
pathways, suggesting it may  be a good therapeutic target. In cancer,
cyclin D-cdk4/6 activity may  be increased by cdk4 and cdk6 ampliﬁ-
cation, mutation of cdk4 to an inhibitor resistant form, or loss of the
INK4 inhibitors. Perhaps the best justiﬁcation for targeting these
molecules comes from clinical trials for the treatment of breast can-
cer, where palbociclib, a cdk4/6 speciﬁc inhibitor, delayed disease
progression in human epidermal growth factor receptor 2 (HER2)+,
estrogen receptor (ER)+ postmenopausal women. In addition, since
cyclin D is transcriptionally linked to mitogenic signaling pathways,
is expressed throughout the cell cycle, is degraded by GSK3 (which
itself is a therapeutic target), and showed managable toxicity in
clinical trials, suggests that cyclin D may  be an important target for
continued drug development [144].
Ampliﬁcation of cyclin E or cdk2 is detected in some tumor
types, but this is rare compared to cyclin D-cdk4/6 [145]. Cyclin
E-cdk2 may  be a good target, as its activation is a major conse-
quence of Rb dependent phosphorylation. However, cdk2 activates
origins of DNA replication, explaining its infrequent deregulation
in tumors. Inactivation of the Rb checkpoint may also trigger cyclin
E-cdk2 independent functions, such as the ability to overcome
senescence. Moreover, several cdk2 inhibitors have failed in clinical
trials for unknown reasons.
6.3. Cdk inhibitors
The cdk inhibitors of the INK4 class block cyclin D-cdk4/6
activity. They do not have additional targets, suggesting that thera-
peutic intervention could be highly speciﬁc. However, therapeutic
restoration of INK4s presented problems, in that these loci are fre-
quently deleted or mutated, which would preclude reactivation.
For many cancers, frequent epigenetic inactivation of INK4 is due to
extensive CpG methylation [146] raising the possibility that natu-
ral products capable of modulating DNA methylation such as EGCG,
folate, and genistein are potential agents capable of reactivating
INK4 genes [147].
The tumor suppressor, p27Kip1, inhibits cyclin E-cdk2, which
would potentially block tumor growth. p27 levels are reduced
S in Can
p
i
a
a
f
c
t
r
c
H
e
s
7
t
A
e
c
t
o
t
o
7
t
i
e
s
t
[
o
i
c
s
t
o
I
c
p

i
t
W
7
(
1
N
i
a
s
s
t
t
e
o
l
t
required for human ovarian CSC metastases [223], in human cervi-
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osttranslationally with increasing tumor grade, resulting in
ncreased cdk2 activity [148]. Re-expression of p27 could be
chieved by interfering with protein turnover. The S-phase kinase
ssociated protein 2 (Skp2) is the E3 ubiquitin ligase responsible
or p27 degradation. Thus, Skp2 and p27 expression is inversely
orrelated [149,150]. Bortezomib-mediated proteosomal inhibi-
ion in multiple myeloma and mantle cell lymphoma [151,152]
esulted in signiﬁcant side effects, suggesting that more spe-
iﬁc targets upstream from the proteasome might be less toxic.
owever, p27 inhibits cdk1 and proliferation of cdk2−/− mouse
mbryo ﬁbroblasts, and also stabilizes the cyclin D-cdk4 complex,
uggesting that targeting p27 may  have global, deleterious effects.
. Molecular pathways regulating tumor proliferation
Most clinically available targeted therapies focus on blocking
he constitutive activation of signal transduction pathways (Bcr-
bl, EGFR, HER2, c-Met, and Raf). While these have initially been
ffective at blocking tumor proliferation, the emergence of resistant
lones is a frequent clinical observation, suggesting that alternate
herapeutic pathways should be investigated. Therefore, this part
f the review will brieﬂy introduce some of the major pathways
hat impact cell proliferation and fate, and that are targets for one
r more natural compounds.
.1. Wnt/ˇ-catenin signaling
Wnt/-catenin signaling is a developmental signaling pathway
hat regulates cell proliferation, differentiation, migration, polar-
ty and asymmetric cell division [153,154]. It plays critical roles in
mbryonic stem cells [155], and can improve reprogramming of
omatic cells toward induced pluripotent stem cells, highlighting
he importance of this pathway for self renewal and pluripotency
156,157].
Aberrant Wnt/-catenin signaling is implicated in numer-
us cancers (e.g., colorectal and breast cancers) [158–162]. Most
nvolve stabilization of -catenin by mutation which is often asso-
iated with tumor aggressiveness. Alternatively, aberrant Wnt
ignaling is due to either the inactivation of negative regulators of
he Wnt  signaling pathway, such as Frizzled related protein [161],
r overexpression of positive regulators, such as disheveled [162].
n Wnt-1 transgenic mice, expanded mammary stem/progenitor
ell populations are associated with the development of preneo-
lastic lesions or tumors [163,164]. Thus, constitutive activation of
-catenin appears to promote the survival and growth of stem cells
n the early stages of tumor formation, suggesting it is an important
arget. Fortunately, there are many natural compounds that block
nt signaling (see below).
.2. Notch signaling
Notch is a family of mammalian transmembrane receptors
Notch 1-4) for membrane bound ligands (JAG1, JAG2, delta-like
-4). Upon binding, Notch receptors undergo cleavage, releasing a
otch intracellular domain, which migrates to the nucleus, where
t targets genes such as cyclin D [165], p21CIP1 [166], NF-B [167],
nd c-myc [168–170]. Notch proteins contribute to angiogene-
is, proliferation, differentiation, and apoptosis [171,172]. Notch
ignaling also contributes to cell fate in embryonic development,
issue homeostasis in adult tissues, and regulates stem cell main-
enance and differentiation [173,174].
Notch signaling is detected in CSCs in breast cancer [175–177],
mbryonal brain tumors [178], gliomas [179], T cell leukemias,
varian, cervical, colorectal, pancreatic, salivary gland, and
ung carcinomas [93,94,178,180–182]. In breast cancer, constitu-
ive activation of Notch prevented differentiation of mammarycer Biology 35 (2015) S25–S54
epithelial cells in vitro and resulted in the appearance of poorly dif-
ferentiated adenocarcinomas [183–187]. Further, HER2 [188–190],
Akt [191], signal transducer and activator of transcription (STAT3)
[101], NF-B [192] were found to cross talk with Notch in breast
CSCs [172], suggesting that Notch could impact breast cancer devel-
opment and proliferation through these signals. In the hypoxic
environment, HIFs activate Notch [3] and the expression of tran-
scription factors such as Oct4 that control stem cell self renewal and
pluripotency [4,193]. Thus, elevated Notch signaling permits CSCs
to survive and proliferate in a hypoxic microenvironment. Natural
compounds, such as resveratrol (see below) [194], down regulate
transcription of the Notch and PI3K/Akt pathways and may prevent
tumor appearance.
7.3. Insulin-like growth factor (IGF) signaling
The IGF-1 receptor/ligand system is implicated in self renewal/
pluripotency in hematopoietic and embryonic stem cells and
supports cell growth/survival by activation of PI3K/Akt and
Ras/Raf/extracellular signal regulated kinase [195–197]. Recently,
Nanog was shown to have a crucial role in maintaining the self
renewal of CSCs through the IGF-1 signaling in hepatocellular
carcinoma [198]. IGF-1 signaling could also crosstalk with other
pathways, such as Notch, EGFR, leptin and promotes the transition
of adult SC to CSCs [172,199,200].
7.4. PI3K/Akt/mTOR signaling
The PI3K/Akt/mTOR pathway plays a central role in growth,
proliferation, motility, survival and angiogenesis in tumor cells
[201,202]. mTOR is a ser/thr kinase that is a downstream target
of PI3K/Akt in many types of cancer. Aberrant activation of mTOR
by mutations or gene ampliﬁcation [203], promotes cancer cell pro-
liferation, EMT  [204], and resistance to anticancer drugs [205,206].
PI3K/Akt/mTOR signaling plays a key role in CSC biology
because this pathway is more sensitive to inhibition compared
to healthy stem cells [191,207]. mTOR inhibition also suppresses
EMT  and CSC-like characteristics in colorectal cancer [208]. How-
ever, inhibition of mTOR is complex because several downstream
targets in this pathway [e.g., mTORC1, S6 kinase 1 and eukary-
otic translation initiation factor 4E binding protein 1 may  be
regulated in an mTOR independent manner [209–214]. Another
challenge is to identify pharmacological proﬁles for mutations
in these pathways. This could be aided using biomathematical
algorithms like the COeXpression ExtrapolatioN (COXEN) model
[215–217].
7.5. NF-B signaling
NF-B transcription factors regulate the expression of key genes
for innate and adaptive immunity, cell proliferation and survival,
and lymphoid organ development. NF-B is activated in many
cancers [218–220] by many divergent stimuli, including proinﬂam-
matory cytokines such as IL-1, epidermal growth factor (EGF), T-
and B-cell mitogens, bacteria and lipopolysaccharides, viruses, viral
proteins, double stranded RNA, and physical and chemical stressors
[220–222]. These events contribute to the link between inﬂam-
mation and carcinogenesis. For example, NF-B activation may  beglioblastoma CSCs from acquiring a mature post mitotic phenotype
[225]. Mammary epithelial NF-B also regulates the self-renewal of
breast CSCs [226]. Thus, NF-B is an important therapeutic target
in carcinogenesis.
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.6. Hedgehog signaling
Hh signaling controls tissue polarity, patterning, and stem cells
aintenance in a variety of tissues [227–230]. In vertebrates, three
h ligands [Sonic Hedgehog (Shh), Desert Hedgehog, and Indian
edgehog] bind to trans-membrane receptors [Patched (Ptch1 or
tch2)]. Upon ligand binding, the complex containing Ptch and its
nhibitor Smoothened (Smo) dissociates. Smo  activates Gli tran-
cription factor which translocates into the nucleus and initiates
ranscription of target genes that regulate the properties of stem
ells [231,232].
Regulation of CSC proliferation in various human tumors includ-
ng glioblastoma, breast cancer, pancreatic adenocarcinoma, MM
nd CML  is through Hh signaling [97,233–241]. Use of the SMO
ntagonist cyclopamine or the Hh ligand neutralizing antibody 5E1
nduced terminal differentiation and loss of clonogenic growth in
astric CSCs from primary tumors [242,243]. Mouse models of CML
lso suggest that Hh regulates the self renewal property of the
umor cells [240], providing an important preclinical model for
ntervention studies with natural compounds. Thus, Hh affects CSCs
elf renewal and differentiation [244]. IL-6 stimulated the growth
f acute myeloid leukemia cells through Hh, and this effect was
locked by the natural compound resveratrol. Shh-Gli signaling
ontrols the characteristics of pancreatic CSCs, and these are inhib-
ted by the use of sulforaphane [132,245].
. Is there a relationship between altered cellular
etabolism and proliferation?
The contribution of altered cellular metabolism to cancer is
xempliﬁed by nonalcoholic fatty liver disease (NAFLD) [246],
hich includes alterations that range from triglyceride accumu-
ation in hepatocytes (steatosis) to steatosis with inﬂammation
nonalcoholic steatohepatitis or NASH), with or without ﬁbrosis
247,248]. NASH patients with liver ﬁbrosis are at risk for the devel-
pment of cirrhosis [249] and hepatocellular carcinoma (HCC). At
he molecular level, altered methionine metabolism plays an essen-
ial role in the molecular bases of NAFLD related HCC.
Chronic liver disease among patients with cirrhosis is partially
haracterized by elevated serum levels of methionine [250,251].
he latter is associated with decreased methionine adenosyltrans-
erase (MAT), and the product of its reaction, S-adenosylmethionine
SAM) [252,253]. MAT  deﬁcient mice developed chronic hepatic
AM deﬁciency, display increased proliferation, and spontaneously
evelop HCC [254]. SAM is a major methyl donor, where it medi-
tes up to 85% of the methylation reactions in the liver, thereby
romoting homeostasis [255]. Since SAM is also a precursor of the
ntioxidant glutathione (GSH), both are decreased in patients with
irrhosis. Treatment of these patients with SAM increased GSH lev-
ls and improved survival [255,256], suggesting the therapeutic use
f SAM to treat liver diseases [257]. Conversely, mice deﬁcient in
he glycine N-methyltransferase gene, which encodes the enzyme
esponsible for SAM catabolism, developed elevated SAM, methio-
ine, serum transaminase levels [258], hepatic steatosis, ﬁbrosis
nd HCC [258–261]. Therefore, altered methionine metabolism
esulted in increased proliferation through decreased levels of MAT
nd GSH.
In cancer, proliferating cells require rapid ATP generation,
ncreased biosynthesis of macromolecules, and maintenance of an
ppropriate cellular redox status [262]. For example, the tumor
uppressor, p53, stimulates glycolytic enzymes and the pentose
hosphate pathway, which provide substrates for macromolecular
ynthesis. In addition, the M2  isoform of pyruvate kinase (PKM2),
hich converts phosphoenolpyruvate to pyruvate, attenuates gly-
olysis, thereby providing precursors for macromolecular synthesiscer Biology 35 (2015) S25–S54 S33
and cell proliferation [263]. In these same reactions, PKM2 also
promotes the development of nicotinamine adenine dinucleotide
phosphate (NADPH) which provides reducing power for macro-
molecular synthesis as well as quenches free radicals. NADPH also
contributes importantly to controlling the redox state of cells. At
low levels, free radicals promote cell proliferation by activating
signaling pathways [264,265]. At moderate levels, free radicals
promote stress responsive genes (e.g., HIF-1)  and cell survival
[266,267], while at high levels, free radicals cause macromolecu-
lar and organelle damage, triggering senescence or apoptosis, and
in surviving cells, activating antioxidant pathways [268,269]. Thus,
the control of free radical levels by cancer cells promotes prolif-
eration but not the appearance of detrimental mutations. In this
context, many natural polyphenols (see below) alter cancer cell
metabolism by reducing intracellular free radicals to very low lev-
els, thereby inhibiting the appearance of mutations and unwanted
proliferation.
9. The role of estrogen and androgen receptors in cancer
cell proliferation
Hormones are signaling molecules secreted by cells that mod-
ulate the function(s) of target tissues. This encompasses paracrine,
autocrine, and intracrine hormonal actions. As one of the main
functions of hormone stimulation is cell cycle regulation, it is
not surprising that hormonal disregulation is involved in can-
cer progression. Hormone related cancers [270] make up almost
30% of all cancer cases, and include cancers of the breast, ovary,
endometrium, prostate, and testis [271].
As cancer initiators, steroid hormones could cause irreversible
damage to the genotype of the cell. For example, high doses and
long term treatment with 17-estradiol (E2) results in DNA damage
among rodents [272,273]. However, it is unlikely that at physio-
logical levels, estrogens and other hormones are carcinogens, and
instead stimulate mitosis by shortening G1 and promoting entry
into S phase [274]. For example, steroid hormones stimulate the
proliferation of normal cells, increasing the chances of a cell acquir-
ing DNA damage and oncogenic mutation as well as cells mutated
by an initiator. Thus, deranged hormone signaling pathways can
promote cancer. However, there is a lack of translational applica-
tions of this information, due to the complicated signals activated
by hormones through their different receptors [275].
Two  estrogen receptors (i.e., ER and ER)  and one andro-
gen receptor (AR) mediate the mitogenic effects of estrogens and
androgens, respectively. After ligand binding, the ligand-receptor
complexes translocate to the nucleus where they recruit cofactor
proteins and the basal transcription machinery onto estrogen or
androgen responsive elements, respectively [274], impacting pro-
liferation at the level of transcription.
Sex steroid hormones also signal through plasma membrane
bound forms of AR and ER [276]. For some cancers, this occurs
through activation of extracellular signal regulated kinase 1 in
the MAPK family and via Akt in the PI3K pathway. These ER-
dependent pathways transduce proliferative, antiapoptotic and
migration signals [277–279]. In this context, membranous ER
staining was observed in up to 1/3 of the cases in which the tumor
was classiﬁed as ER negative on the basis of ER nuclear expres-
sion. Membrane ER expressing breast cancers also show a strong
positive correlation with phosphorylated Akt and HER2 overex-
pression [280], the latter of which is characteristic of ‘invasive
carcinoma’ [281]. In addition, ER plasma membrane localiza-
tion and its interactions with IGFR1 and EGFR/ErbB2 may  be one
of the mechanisms underlying the development of drug resis-
tance in breast cancer cells [282,283]. Androgen independent
prostate cancer is also mediated by IGFR-1/IGF-1 [284] and elevated
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GFR/ErbB-2 [285], combined with downstream Akt [286,287] and
anus kinase (JAK)/STAT [288] and MAPK signaling. These path-
ays activate AR, which translocates to the nucleus, where it alters
ost gene expression that promotes cell survival, proliferation, and
etastasis. As indicated below, there are a number of natural com-
ounds which target one or more of these pathways. While the
uccess of surgical or medical castration has been demonstrated
n androgen dependent tumors, the utility of natural compounds
n androgen independent tumors will depend upon the mech-
nisms whereby androgen independence is achieved. This may
nclude AR overexpression, AR mutations, altered recruitment of
ranscription cofactors, and/or sustained intratumoral synthesis of
ihydrotestosterone, which binds to and activates the AR in the
ndrogen dependent phase of prostate cancer [289].
Deregulation of ER-  and ER-mediated signal transduction,
ogether with the deregulation of nuclear receptor activities, may
xplain the role of estrogen in promoting breast cancer [275]. In
his respect, ER positive breast tumors are treated with drugs that
nterfere with the availability of endogenous E2 (e.g., aromatase
nhibitors) or ER transcriptional activity (e.g., 4OH-tamoxifen)
290]. The same drugs could act on ER signaling, even if the
xpression of this receptor subtype is inversely correlated with
he development of several cancers [291]. Thus, a selective ago-
ist for ER could promote strong antiproliferative intracellular
ignals in breast, colon, and prostate tissues, where ER func-
ions as a growth repressor and a dominant negative inhibitor of
R-mediated proliferation [292,293]. In spite of these data, the
ole of the membrane initiated ER signaling in tumors has been
nderestimated. Nuclear localization of ERs [294,295] is now con-
idered to have prognostic signiﬁcance. Very few drugs for breast
ancer have been shown to target ERs extranuclear mechanisms
283].
Anticancer drug development has been characterized by two
ifferent approaches: the chemical modiﬁcation of preexisting
herapeutics and the selection of new molecular targets. The lat-
er approach better overcomes the limitations of available clinical
reatments and could provide an opportunity to expand antihor-
onal treatments in new directions. A further promising strategy
ould rely on targeting ER membrane proliferative actions, but this
emains to be explored.
0. The impact of stromal cells on tumor growth
Stromal components in tumor microenvironment contribute
entrally to tumor progression and metastasis. Reciprocal inter-
ctions occur between neoplastic cells and stromal components
eading to coevolution. In this context, either stromal cells support
ransformation of epithelial cells, or transformed tumor cells
ngage stromal cells, and the altered environment can inﬂuence
he metastatic, dormancy related, and stem-like potential of tumor
ells [296]. The stromal compartment of the tumor is complex,
onsisting of inﬂammatory/immune cells, endothelial cells (vas-
ular), pericytes, ﬁbroblasts, adipocytes and extracellular matrix
omponents (e.g., collagen, ﬁbronectin, laminin and proteoglycan
omplex). Tumor inﬁltrating inﬂammatory cells release EGF, VEGF,
broblast growth factor-2 (FGF-2), chemokines, cytokines, and
roinvasive matrix degrading enzymes to promote tumorigenesis
47,297,298]. Continued tumor growth and progression is medi-
ted by the “angiogenic switch,” which occurs in response to VEGF
nd FGF-2 secreted from tumor cells, resulting in angiogenesis
299–301]. Adipocytes in the tumor microenvironment produce
adipokines’ [302,303] such as leptin, adiponectin, hepatocyte
rowth factor, collagen VI, IL-6 and TNF-, which are important
or tumor growth. Fibroblasts in the tumor microenvironment
rovide the structural framework of the stroma [304]. Fibroblastscer Biology 35 (2015) S25–S54
remain quiescent, but they proliferate during wound healing,
inﬂammation and cancer. Paracrine factors from tumor cells acti-
vate ﬁbroblasts to become “cancer associated ﬁbroblasts” (CAF)
[305,306]. CAFs secrete factors that modulate tumor growth and
modify the stroma to facilitate metastasis [307,308] and attenuate
responses to anticancer therapies [309,310]. Thus, tumor stromal
crosstalk is important when developing therapeutic options, since
tumor centric approaches may  not work in a stroma rich tumor
microenvironment.
11. Natural and dietary substances that block cancer
proliferation and augment anticancer therapy
More than half of current drugs originally came from natural
products. Plant derived anticancer agents that block proliferation,
resulting in cell cycle arrest and apoptosis, include vinblas-
tine, etoposide, teniposide, homoharringtonine and camptothecin
derivatives [311]. Epidemiological studies have shown that natu-
ral products and nutritional substances may  be active in cancer
chemoprevention. These have been most extensively described in
colon, prostate and breast cancers.
Contrary to conventional chemotherapy, which exhibits cyto-
toxic effects against all dividing cells, targeted therapeutic drugs
are active against proliferating cells involved in tumor progression.
Targets of these therapeutic approaches include Bcr-Abl kinase
(e.g., imatinib [312], nilotinib [313], and ponatinib [314]), EGFR
(geﬁtinib [315] and erlotinib [316]), HER2/ErbB2 (lapatinib [317]),
and c-Met (crizotinib [318]). Although initially effective, relapse is
common, resulting in the appearance of drug resistance, the acti-
vation of alternative signaling pathways, and/or the generation
of chemoresistant CSCs [319,320]. Given that cancer is multi-
step, targeting multiple pathways may  yield stronger antitumor
activities. Accordingly, some of the leading natural compounds
used in cancer therapy and in chemoprevention are presented
below as examples of their potential utility in the pathogenesis of
cancer.
11.1. Curcumin
Curcumin (diferuloylmethane), a yellow spice and pheno-
lic compound derived from the plant Curcuma longa, is one of
the most powerful and promising chemopreventive and anti-
cancer agents [321] (Fig. 5). The consumption of a curcumin
rich diet is inversely correlated with several human malignan-
cies [322]. Curcumin blocks cancer cell proliferation by targeting
Wnt  (Table 2), NF-B, STAT3, PI3K/Akt [323] (Fig. 6) and mTOR
[324]. Curcumin also has fewer side effects than conventional
therapy [325,326]. Curcumin indirectly affects tumor prolifera-
tion by altering the expression miRNAs, which regulate cellular
signaling implicated in tumor cell proliferation. For example, the
antiproliferative activity of curcumin against pancreatic cancer
cells has been shown to be mediated by modulating the miR-
200 family, which in turn regulates EMT  [327]. Further, curcumin
and its synthetic analog, diﬂourinated curcumin, downregulate
miR-21 expression [328] and reduced the expression of Bcl-2 by
upregulating miR-15a and miR-15b [329], indicating that curcumin
impacts upon proliferation, in part, by epigenetic mechanisms. A
major problem with curcumin is its low bioavailability, prompting
the development and evaluation of structural analogs of cur-
cumin, stabilization of curcumin with adjuvants (e.g., piperine),
liposomal and nanoparticle associated curcumin, and the devel-
opment of curcumin phospholipid complexes, aimed at increas-
ing bioavailability while antitumor properties are maintained
[330].
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Table  2
Summary of selected natural compounds active against Wnt  signaling in cell proliferation.
Compound Effects Cancer model Concentration/dose References
EGCG Reduced nuclear -catenin; blocks
-catenin/TCF mediated
transcription; increase Wnt
inhibitor (WIF1)
Non small cell lung cancer
(NSCLC) cells, breast cancer
cells; familial adenomatous
polyposis (APCMin/+) mice
NSCLC 0–50 M;  breast:
0–100 M
APC mice: high fat diet + 0.16%
EGCG
[436–439]
Resveratrol Inhibits -catenin migration to
nucleus; disrupts -catenin/TCF
binding
Colorectal cancer cells 0–20 M [440,441]
Genistein Suppresses -catenin/TCF
mediated transcription;
up-regulates GSK3 and
E-cadherin; blocks Wnt  signaling
by down-regulation of miR-1260b;
increase in DKK1
Gastric, renal, prostate, and
colorectal cancer cells
Gastric: 0–100 M;  renal:
25 M;  prostate: 25–50 M;
colorectal: 75 M
[442–447]
Curcumin Decreases nuclear -catenin;
blocks -catenin/TCF-mediated
transcription; down-regulates
Wnt4, GSK3 and Frizzled
Breast and colorectal
carcinoma cells;
neuroblastoma cells
Breast: 0–70 M;  colorectal:
20 M;  neuoblastoma:
0–20 M
[448–451]
Vitamin A Inhibits Wnt/-catenin signaling;
vitamin receptor competes with
-catenin for TCF; blocks GSK3
Transformed human bronchial
epithelial cells
4 M [452]
Vitamin D Inhibits -catenin signaling,
induces E-cadherin
Colorectal carcinoma cells 0.1 M [453,454]
Lycopene Reduced nuclear -catenin via
attenuating GSK-3
phosphorylation
Prostate cancer clinical trials 5–50 mg/kg [455]
ap-XSC + docosahex-aenoic
acid -3 fatty acid
Target(s) unknown Colorectal cancer 2.5–5 M [434]
ap-XSC Pathway target(s) unknown Apc mice a model for familial
adenoma
High fat diets containing 10–20 [435]
a 1,4-phenylene bis(methylene) selenocyanate.
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kinases (e.g., Src) [344,345] (Fig. 6). Resveratrol also inhibits theig. 5. Examples of anti-proliferative compounds obtained from natural sources.
1.2. Indole-3-carbinol, 3,3-diindolylmethane, sulforaphane and
rassinin
Indole-3-carbinol, a natural hydrolysis product of glucobrassicin
n cruciferous vegetables (Fig. 5), blocks tumor cell proliferation by
odulating expression of the IGFR1, the insulin receptor substrate-
, and by triggering degradation of the ER [331]. Such vegetables
lso contain sulforaphane, a naturally occurring organosulfurtous polyposis p.p.m.
compound formed by the hydrolysis of glucosinolates. Sul-
foraphane may  lower the risk of colon, prostate, and perhaps other
cancers [332]. sulforaphane blocks proliferation, induces cell cycle
arrest in vitro, and has anticancer activity in animal models [333].
Sulforaphane also suppresses NF-B and the Wnt/-catenin self
renewal pathways in CSCs [334,335] (Fig. 6). Sulforaphane appears
to synergize with sorafenib in shrinking pancreatic cancer by block-
ing proliferation, angiogenesis, and EMT  [336]. Another indole
compound derived from cruciferous vegetables, brassinin, arrests
cancer cells in G1 via blocking PI3K signaling and upregulating
p21 and p27 [337]. In comparison, 3,3-diindolylmethane increased
the expression of miR-21 which reduced the expression of its
target gene, cell division cycle 25 homolog A [338]. Moreover, 3,3-
diindolylmethane has been shown to increase the level of the miR-
200 family in pancreatic cancer cells, which impacts EMT  [327].
11.3. Resveratrol
Resveratrol (3,4′,5-trihydroxy-trans-stilbene) is a polyphenolic
compound found in the skin of grapes, in red wine, peanuts and
mulberries (Fig. 5). Resveratrol appears to have antiaging prop-
erties, cardiovascular protective and cancer prevention activities
[339–341]. In cancer prevention, resveratrol blocks proliferation,
promotes cell cycle arrest, and induces apoptosis by suppressing
extracellular signal regulated kinase signaling, p53, Rb/E2F, cyclins
and cdks. It sensitizes cells to extrinsic (Fas and TNF related apo-
ptosis inducing ligand mediated) apoptosis by facilitating death
receptor localization into membrane lipid rafts [342] and promotes
intrinsic (mitochondrial) apoptosis, in part, by inhibiting survivin
and Bcl-XL [343]. Resveratrol suppresses the activity of transcrip-
tion factors involved in proliferation (e.g., NF-B, activating protein
1 and the early growth response protein 1), MAPKs and tyrosineproliferation of prostate cancer cells by inhibiting AR transcrip-
tional activity, stimulating PTEN expression, and by blocking Akt
phosphorylation [346]. Resveratrol blocks the activity of -catenin
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Fig. 6. Impact of various natural compounds upon selected growth promoting sig-
naling pathways. When proliferation is triggered by growth factor signaling, there
are  a number of natural compounds that could inhibit growth. For example, vitamin
A,  which promotes differentiation, downregulates ras signaling. Resveratrol could
block downstream signaling components such as ERK, AP-1, and alternative path-
ways, such as Hedgehog. Other signaling pathways that promote growth, such as
Wnt, cytokine triggered STAT signaling, and receptor mediated activation of NF-
B,  could be blocked, in part, by a variety of natural compounds. This suggests
that a combination of natural compounds could have a signiﬁcant impact upon
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totic proteins Bcl-XL and Bcl-2 [378]. However, EGCG promotedroliferation, even at early stages of carcinogenesis, by inhibiting normal signaling
athways.
y preventing its accumulation in the nucleus as well as binding to
ranscription factor 3 [346] (Table 2). Resveratrol suppresses IGFR1
nd Wnt  pathways in colon cancer cells [347]. Thus, in vitro studies
trongly support a role for resveratrol in mediating cell cycle arrest
r triggering apoptosis.
Ingestion of resveratrol rich grape powder in humans sup-
ressed expression of the Wnt  target genes, cyclin D1 and axin in
ormal colonic mucosa, suggesting that Wnt  pathway inhibition
ay  contribute to resveratrol-mediated colon cancer prevention
348]. Constitutively activated Wnt  is also proinﬂammatory [349].
ince many cancers are associated with prolonged inﬂammation
nd chronic tissue damage, resveratrol may  also prevent tumor
nset by attenuating the regenerative responses that accompany
rolonged inﬂammation.
Resveratrol blocks PI3K and Akt signaling, which strongly
romote growth [350], by downregulating cdk2, cyclin D1 and
roliferative cell nuclear antigen. In ovarian cancer, resveratrol
ownregulates Akt and ERK signaling [351] (Fig. 6) and may  inhibit
rostate cancer growth via the Akt/miR-21 pathway [352]. Resver-
trol also suppresses phosphorylation of the NF-B inhibitor, IB
353], thereby inhibiting NF-B [354]. Resveratrol also inhibits Hh
355] and Jak2/STAT3 signaling [356], which contribute to cell pro-
iferation and cancer progression (Fig. 6, Table 3), suggesting that
t may  be useful in vivo.cer Biology 35 (2015) S25–S54
Resveratrol was shown to inhibit proliferation and NF-B sig-
naling in chemically induced rat liver carcinogenesis [357,358].
In addition, resveratrol affected the expression TGF- and fork-
head box protein C2 by regulating miR-520h [359], suggesting that
resveratrol, like cucumin, mediates its effects via epigenetic mech-
anisms. Although most in vivo studies show that resveratrol has
antitumor activity, its antiaging properties are paradoxical in that
they promote cell survival [360,361]. These differences may  depend
upon bioavailability and serum concentrations and underscore the
need to conduct carefully crafted clinical trials in the future. For
example, the doses of natural compound(s) used for chemopreven-
tion in “healthy” patients may  be different than the generally higher
pharmacologic doses given to patients already diagnosed with can-
cer, since in the former group, toxicity should be low, while in the
latter group, the risk vs. beneﬁt ratio would be more important.
11.4. Flavonoids
Flavonoids are polyphenolic herbal constituents with a wide
range of antiallergic, antiinﬂammatory, antioxidant, antimicro-
bial and anticancer activities. Flavonoids inhibit hormone related
cancers by modulating the activities of sex steroid hormone recep-
tors [283,362,363]. Upon receptor binding, ﬂavonoids reduce ER
association with the plasma membrane, impair ER dependent
proliferative signaling cascades, and promote apoptosis through
the activation of ER-mediated p38/MAPK [364–366]. This may
explain the inverse correlation between the dietary consumption
of ﬂavonoids and the incidence of hormone related breast, prostate,
testicular, and colorectal cancers [367,368]. While data support
the potential medicinal use of ﬂavonoids for the treatment of ER
related cancers, their low bioavailability [369], combined with the
length of time it takes to run human clinical trials, has limited their
use. Flavonoids were reported to exhibit a comparable activity to
that of well known P-glycoprotein [P-gp] inhibitors (e.g., verapamil
and cyclosporine), without toxicity to normal cells [370]. Thus,
ﬂavonoids have the potential of being useful as chemotherapeutic
agents, through derivatives with increased bioavailability, as is the
case with paclitaxel and vincristine in multidrug resistant tumor
cells [371,372].
11.5. EGCG
Green tea is associated with decreased frequency of cancer
development due to the presence of EGCG and other polyphenols
(Fig. 5). EGCG suppresses AR expression and signaling. EGCG also
blocks the nuclear translocation of NF-B as a result of decreased
inhibitor of NF-B kinase activity, thereby blocking cancer cell pro-
liferation. Green tea polyphenols also downregulate MAPK activity
and VEGF production leading to a block in proliferation [373]. In
addition, EGCG inhibits -catenin nuclear accumulation and sub-
sequent transcription of target genes (Fig. 6, Table 2). EGCG also
exerts part of its anticancer activity through epigenetic mecha-
nisms. For example, EGCG can reverse CpG island hypermethylation
of various methylation silenced genes and reactivate their expres-
sion [374]. EGCG also upregulates such miRNAs as miR-16, let-7c,
miR-18, miR-25, and miR-92 and downregulates miR-129, miR-
196, miR-200, miR-342, and miR-526 [375]. Furthermore, EGCG
affects the expression of HIF-1 through the regulation of miR-210
[376]. EGCG protects against oxidative damage of DNA, proteins
and lipids by acting as a chaperone, and by downregulating mul-
tiple signaling pathways (e.g., VEGFR1/R2, EGFR/HER2, PI3K/Akt,
IGF/IGFR1, and MAPK) [377], and strongly inhibits the antiapop-DNA damage in mouse leukaemic monocyte macrophage RAW
264.7 and human promyelocytic leukemia HL-60 cell lines in a dose
dependent manner [379]. EGCG has also been associated with liver
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Table  3
Summary of selected natural compounds active against Hh signaling in cell proliferation.
Compound Effects Cancer model References
Zerumbone Induces apoptosis Leukemia, breast cancer [456,457]
Sulforaphane Inhibits Shh signaling by blocking Gli
transcription, proliferation and
induction of apoptosis.
Pancreatic CSCs [132,245]
Cyclopamine Targets Smo protein Targeted CSCs in murine
medulloblastoma, pancreatic and
breast cancers
[180,458,459]
Curcumin 95% inhibition of Gli1 mRNA; 80%
down-regulates Gli reporter activity
Medulloblastoma cells [460]
Apigenin, Baicalein, EGCG, Curcumin, Genistein, 95% inhibition of Gli1 mRNA; 80%
porter
Prostate cancer cells [461]
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aQuercetin, Cyclopamine, Resveratrol down-regulates Gli re
EGCG 95% inhibition of Gli1 
down-regulates Gli re
amage, perhaps because it triggers oxidative stress [380]. In light
f these results, it is likely that the multiple properties and targets
f EGCG and many other natural compounds (Fig. 6, Table 5) impact
he outcome of treatment, depending upon dose, duration, and
ombinations with other therapeutic approaches. In this context,
areful consideration must be given to the use of these compounds
n the development of novel therapeutics.
1.6. Genistein
Genistein is an isoﬂavone in soy that inhibits proliferation
f breast cancer cells and has colon cancer prevention activ-
ty [381,382] (Fig. 5). Genistein blocks NF-B [383], promotes
poptosis and alters polyamine metabolism [384]. It exerts antipro-
iferative activity by blocking EGF signaling through forkhead box
3 activity [385,386], has antitumor effects in a non small cell lung
ancer cell line [387], regulates the expression of miRNA impli-
ated in controlling proliferation [388], and exhibits additive effects
hen combined with trastuzumab and cetuximab in breast and oral
quamous cell carcinoma cells, respectively [389,390]. Genistein
uppresses prostate carcinogenesis in the transgenic adenocarci-
oma of the mouse prostate model via inhibition of -catenin
ignaling [391]. Treatment also reduced Wnt  signaling in mam-
ary epithelial cells [392] and in a colon cancer cell line [393]
Fig. 6, Table 2). Genistein inhibits -catenin/TCF transcriptional
ctivity, promotes GSK3- activation (which phosphorylates and
romotes degradation of -catenin), and upregulates expression
f E-cadherin (Fig. 6, Table 2). As a phytoestrogen, genistein acts
hrough binding to the ER. ER activation leads to cell prolifer-
tion [394], and ER activation promotes cellular differentiation
395]. ER signaling counteracts ER related proliferation. Genis-
ein preferentially activates ER-mediated gene transcription [396]
hich would inhibit proliferation (and tumorigenesis) and pro-
ote differentiation. In addition, genistein affects the expression
f miRNAs [388], such as upregulating miR-200 [327]. However,
ts therapeutic actions in vivo have not been consistent, in that
enistein exhibited a cancer promoting effect in some tumors [397],
uggesting the need for careful selection of patients and safer plan-
ing in future clinical trials. This may  be concentration dependent,
ecause genistein inhibited cell proliferation at high concentrations
nd activated of estrogen signaling at low concentrations [330]. In
rder to better exploit the potential of genistein and limit off tar-
et effects, it has been coupled to a monoclonal antibody (B43) and
hen used for the treatment of patients with acute lymphocytic
eukemia and Non-Hodgkin’s lymphoma [398]. Genistein has also
een coupled to recombinant EGF and then used to treat patients
ith EGFR+ breast cancer [399]. Additional human studies, where
enistein is coupled to speciﬁc ligands, need to be conducted to
ee whether genistein’s antitumor properties can be demonstrated
lone or with cytotoxic or radiation therapy. activity
; 80%
 activity
Chondrosarcoma cells [462]
11.7. Ellagitannins
Ellagitannins are bioactive polyphenols found in berries and
pomegranates that have anticancer, antioxidant and antiinﬂam-
matory bioactivities (Fig. 5). Ellagitannins are not absorbed intact
into the blood stream but are hydrolyzed to ellagic acid. They are
also metabolized by gut ﬂora into urolithins that are bioactive and
inhibit prostate cancer cell proliferation by interfering with NF-
B activity [400]. Ellagitannin rich pomegranate extract inhibited
proliferation of endothelial and prostate cancer cells, and blocked
tumor associated angiogenesis [401]. Urolithin signiﬁcantly inhib-
ited testosterone induced MCF-7aro cell proliferation most likely
by exhibiting antiaromatase activity [402]. In animal studies, ellag-
itannin rich pomegranate fraction has been shown to retard cell
proliferation through suppression of -catenin and NF-B path-
ways in diethylnitrosamine induced hepatocarcinogenesis in rats
[403,404]. In clinical studies, pomegranate juice led to a decrease
in prostate speciﬁc antigen (PSA) levels after primary treatment
with surgery or radiation [367]. Furthermore, ellagitannins were
also active in regulating the expression of several miRNAs in HepG2
cells [405].
11.8. Lycopene
Lycopene is a lipid soluble carotenoid molecule found in high
concentration in red fruit and vegetables. Lycopene has a signiﬁcant
antioxidative activity. Epidemiological studies have shown that
consumption of lycopene is inversely related to human prostate
cancer [406,407]. Lycopene blocked cell growth in breast, prostate
and endometrial cancer cells by inhibiting NF-B activity [408].
In colon cancer cells, lycopene inhibited Akt signaling. Lycopene
treatment suppressed Akt activation, increased the phosphory-
lation (inactivation) of -catenin, and stimulated expression of
cdk inhibitor p27Kip1 [409]. In addition, lycopene inhibited IGF-1-
mediated Akt and AR signaling in rat prostate cancer and reduced
AR and -catenin nuclear localization [410]. Independent evidence,
however, failed to show that lycopene altered cell proliferation for
a variety of cell types [411]. Given these circumstances, lycopene
and many other natural products are currently available as herb
and vitamin supplements that are not regulated by the Federal Drug
Administration. Although these supplements have no serious side
effects, future work will be needed to clarify the use of lycopene in
cancer therapy.
11.9. QuercetinQuercetin, a natural protective bioﬂavonoid, possesses diverse
pharmacologic effects, such as antioxidant, antiinﬂammatory,
antiproliferative, and antiangiogenic activities. Quercetin, at non-
toxic concentrations, signiﬁcantly inhibited Akt and mTOR.
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Table  4
Clinical trials using natural products.
Target Drug Type of cancer Phase Other agents References
Notch aMK0752 Pancreatic I, II
Gemcitabine/radiation
[463,464]
Breast I
bRO4929097 Renal cell II
Cetuximab, bevacizubmab/FOLFOX
vismodegib
[465]
Colorectal II
Advanced breast I
Advanced/metastatic sarcoma
Hedgehog cSaridegib.svg (IPI-926) Head and neck I
Cetuximab bevacizumab,
chemotherapy
[466,467]
Colorectal II
BCC II
Solid tumors I
Hedgehog/Notch bRO4929097 Breast I Vismodegib [465]
dBMS-833923 BCC, solid tumors I Dasatinib or bosutinib [468,469]
ePF-04449913 Hematologic I [470]
Wnt Resveratrol Colon I, II [471,472]
fPRI-724 Solid tumors I [473]
a 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-diﬂuorophenyl)cyclohexyl)-propanoic acid is a -secretase inhibitor.
b 2,2-dimethyl-N-((S)-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl)-N′-(2,2,3,3,3-pentaﬂuoro-propyl)-malonamide is a -secretase inhibitor.
c Saridegib is a cyclopamine (2-hydroxylpropyl)--cyclodextrin) which is a Smoothened (SMO) inhibitor.
azolin-2-yl) amino)benzamide is a Smoothened inhibitor.
l)-3-(4-cyano-phenyl)urea is a SMO  inhibitor.
BP (the binding protein of the cAMP response element-binding protein CREB).
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Table 5
Natural Compounds Effective Against Proliferation.
Natural product Targets
Curcumin NF-B, PI3K/Akt, and STAT3 [323],  mTOR [324];
HIF-1 [474]
Sulforaphane NF-B [334], Wnt  (-catenin) [335], Hh [132]
Resveratrol NF-B [353], AR [346], IGFR1 [347],  Notch-1 [194],
Cyclin/CDKs [350], Wnt  (-catenin) [348], STAT3
[356], PI3K/Akt [346], Hh [355]
Genistein NF-B [383], FOXO3 [385], Wnt  (-catenin)
[391,392], ER [396]
EGCG NF-B, VEGFR1/R2, EGFR/HER2, PI3K/AKT, IGF/IGF1,
MAPK, COX-2 [377]
Brassinin PI3K/Akt [337]
Indole-3-carbinol ER,  IGFR1, and IRS-1 [331]d BMS-833923 N-(2-methyl-5-((methylamino)methyl)phenyl)-4-((4-phenylquin
e PF-04449913 (1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-y
f PRI-724 speciﬁcally inhibits the recruiting of beta-catenin with its coactivator C
oreover, quercetin exhibited antitumor activity that was mani-
ested by a signiﬁcant reduction of tumor size in a xenograft mouse
odel [412]. Quercetin inhibited P-gp function and consequently
nhanced the bioavailability of chemotherapeutic agents [413].
urthermore, tamoxifen underwent extensive hepatic metabolism
s a substrate for the efﬂux of P-gp, breast cancer resistance protein,
nd multidrug resistance protein 2. As a dual inhibitor of the metab-
lizing enzyme cytochrome P450, family 3, subfamily A and the
ultidrug resistance transporter, quercetin increased the absorp-
ion and the bioavailability of tamoxifen [414].
1.10. Additional natural products
Additional natural products were also reported to affect tumor
roliferation such as 13-cis-retinoic acid which signiﬁcantly inter-
eres with the activity of NF-B, c-Fos, activated transcription
actor-2, and cyclic adenosine monophosphate response element
inding protein that directly or indirectly modulate tumor prolifer-
tion [415]. Other natural products, such as parthenolide, the active
omponent in Feverfew (Tanacetum parthenium), also showed
trong anticancer and antiinﬂammatory activities. Parthenolide
xhibited strong NF-B- and STAT-inhibition mediated transcrip-
ional suppression of proapoptotic genes [416]. In addition to the
ntiproliferative activity of pure natural products, there are many
romising medicinal plants and mushrooms [417]. For example,
itter melon (Momordica charantia), which is used as functional
ood to prevent and treat diabetes and associated complications,
xhibited antitumor activity against a number of cancer cell lines
ithout affecting normal cell growth [418]. Moreover, organic
xtracts of medicinal mushrooms, such as Ganoderma lucidum and
omatus caprinus, exhibited strong and promising antiprolifera-
ive activities against a variety of cancer cell lines [419–422]. To
ppreciate their full potential for future clinical use, isolation and
lucidation of active chemical entities will be required, followed by
reclinical and clinical evaluation.
1.11. Natural compounds in clinical trialsAlthough clinical data on natural products in cancer appears
fﬁcacious, most studies have not been conducted as randomized
linical trials. Appropriate clinical trials have begun with someQuercetin ER [365], HER2 [475], mTOR [476]
Lycopene NF-B [477], IGFR1 [410], PI3K/Akt [409], Wnt
(-catenin) and AR [478], cyclins/CDKs [479]
natural compounds (Table 4), and these will be important for
the development of stand alone or combination therapies. The
goal of natural products or herbs is not to replace current cancer
therapeutics but rather to augment their activity as adjuvants or
to reduce side effects. Existing studies suggest synergistic inter-
actions between cancer chemotherapeutics and natural products,
especially when these two approaches act on cancer by different
mechanisms. For example, lycopene supplements reduced tumor
size and PSA levels in localized prostate cancer patients [423],
which is consistent with the inhibition of AR nuclear translocation
that was found by in vitro studies. Many of these bioactive natural
products are consumed in diets, suggesting a need for developing
“medicinal foods.” The latter will be based on phytochemicals
directed against speciﬁc molecular targets that might be utilized
as a diet based combinatorial approach in the prevention and
treatment of cancer [424]. Table 5 presents a list of priority targets
and corresponding natural products discussed herein. This could
provide a foundation for the future research and development
of these compounds or their derivatives that would be useful
in cancer prevention and/or treatment. However, several “best”
targets are not listed because so far there is no natural product
that affects these molecules (e.g., Snail/Slug). In addition, several
other phytochemicals have been evaluated over the past decade
against a variety of different tumor types [330]. In some cases,
plant extracts were used, even though the active phytochemical(s)
in Cancer Biology 35 (2015) S25–S54 S39
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ere not known. Further, when puriﬁed compounds were used,
hey often potentially blocked the activities of multiple molecules
r pathways, making it difﬁcult to assess their relevant targets
330]. While the compounds in Table 5 have been selected for their
ctivities against proliferation, many of them may  also impact upon
ther hallmarks of cancer. For example, many of these chemicals
ave additional antiinﬂammatory and antioxidant effects, includ-
ng their ability to scavenge free radicals. In generating a single
prototypical” approach for the treatment of preneoplastic and
arly tumor nodules with natural compounds, a combination of
urcumin, genistein and resveratrol is suggested because they each
ave broad activities against many of the key signaling pathways
nd targets that drive proliferation. However, the concentration
f these phytochemicals used experimentally in in vitro studies
astly exceeds the concentration detected in humans following
egetable and fruit intake. Thus, more stable, absorbable variants
ill have to be derived in order for these to be considered as
hemopreventative or chemotherapeutic agents. The bioavail-
bility, pharmacokinetics (especially when complex mixtures are
eing evaluated), isolation without copurifying contaminants (e.g.,
eavy metals), degradation proﬁles in human tissues, favorable
rug–drug interactions in preclinical and clinical trials, and off
arget effects when used at doses that will probably exceed
hose found in the dietary sources will need to be determined. In
ddition, reproducible isolation of active compounds from natural
ources is likely to be challenging. This is because activity may
epend upon combinations of compounds that may  be present in
ixtures but separated during isolation, and because the amounts
f these natural compounds produced by the plant or other host
rganism are likely to vary depending upon the environmental
onditions in which these hosts grow. Thus, climate changes could
reatly effect the reproducible isolation and characterization of
ompounds from natural sources. An alternative approach would
nvolve chemical synthesis of active natural compounds, but the
omplex chemical structure of many compounds make them
ifﬁcult or impossible to synthesize by conventional means. In this
ase, the key enzymes or metabolic pathways responsible for their
ynthesis could be isolated and transferred to easily manipulated
acteria or yeast to achieve synthesis of enough material for
herapeutic applications. However, as the mechanism(s) whereby
hese natural products operate are elucidated, better comple-
entation with other drugs (natural or synthetic) may  provide
pportunities to target proliferation at the appropriate time in
he right cell type. Overcoming these limitations will provide an
ven broader base for their utility in cancer chemoprevention and
n blocking tumor progression. Even if natural products are not
uitable alone or in combination for cancer chemoprevention, they
ay  be useful as an adjuvant to chemotherapy, radiation therapy,
nd/or small molecule inhibitors of key signaling molecules. This
ould prompt the design of clinical trials in which one or multiple
atural products (or their derivatives) will be added to standard
are therapy for individual tumor types, to see if they are active
n reducing tumor burden and/or decreasing the frequency of
elapse. Among tumor types where clear risk factors of cancer
evelopment are known, natural products could be evaluated to
ee whether they reduce the risk factors for tumor development.
2. Emerging genomic and bioinformatic tools to facilitate
pplication of natural compounds to cancer
The “genomics revolution” is transforming the understanding
f cellular processes involved in cancer such as cell prolifera-
ion, differentiation, and apoptosis. The Human Genome Project
425] provided the groundwork by generating human and model
rganism genome assemblies [426–429], new genome based tech-
ologies [430,431], and advanced computational infrastructureFig. 7. Evolution of genomic resources aimed at identiﬁcation of cancer targets.
There are a growing number of accessible genomic resources that provide an empir-
ical  foundation to identify genome-wide targets of tumor cell proliferation.
to handle newly generated massive datasets. New sequencing
technologies are now outﬁtting researchers with unprecedented
volumes of data to explore the etiology of cancer. For the ﬁrst time,
biologists are able to characterize how entire genomes, transcrip-
tomes, proteomes, and epigenomes can respond to speciﬁc changes
in genes and their cellular environments, including insights into
underlying mechanisms of proliferation. By applying an integra-
tive systems approach, cancer biologists are beginning to employ
an enormously powerful perspective with important translational
consequences. These tools will be critical in assessing the impact of
natural compounds, alone or in combination, for cancer prevention
and treatment.
Novel genomic data are accumulating at an ever increasing rate.
Massive genome wide surveys of tumor and nontumor genomes
from the Cancer Genome Project are providing new opportunities
to track how cancers develop over time [432] and ﬁnd common
molecular mechanisms that could be therapeutically targeted. The
ENCODE project has functionally annotated genomes with great
precision [433]. Perhaps, the single most important feature of these
data is that they are freely available via publicly accessible and
expertly curated databases (e.g., NCBI’s GenBank, Sanger Institute,
University of California, Santa Cruz Genome Browser) allowing
for greater opportunities to transform cancer research from single
genomic phenomena to systems wide analyses (Fig. 7). As a result,
bioinformatics has become a critical interdisciplinary tool enabling
researchers to handle, analyze, mine, and explore high through-
put data. Bioinformatics will become even more important as new
genomic technologies increase the super exponential rate at which
tumor based data of all sorts are generated.
In the postgenomics era, there is a transformational shift in
the understanding of gene regulation, mutational changes, and
epigenomic consequences in cell proliferation at the genomic level.
While the study of cancer represents a difﬁcult challenge due to the
sheer diversity and complexity of its multiple genetic factors, the
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Table 6
Priority targets for sustained proliferative signaling.
Other cancer hallmarks Targets for sustained proliferationa
(inhibits)
HIF-1 signaling
(inhibits)
NF-B signaling
(inhibits)
PI3K/Akt signaling
(inhibits)
Wnt  (-catenin)
(inhibits)
IGFR1 signaling
(attenuates)
Cell cycle
(CDKs/cyclins)
(suppresses)
AR signaling
(suppresses)
ER signaling
Genomic instability +
[480,620] b
+
[481]
+
[482]
0 0 +
[483]
+
[484]
+
[485]
Tumor-promoting inﬂammation +
[486]
+
[487,488]
+
[489–491]
+
[492–494]
+
[495,496]
+
[497,498]
+/−
[499,500]
+/−
[501,502]
Evasion of anti-growth signaling 0 +/−
[503]
+
[504,505]
+
[506,507]
+
[508,509]
+
[510,511]
+
[512–514]
+
[515,516]
Resistance to apoptosis +
[517,518]
+
[519,520]
+
[521]
+
[522]
+
[523]
+
[524]
+
[525]
+
[526]
Replicative immortality +
[527]
+/−
[225,528,529]
+
[530–532]
+/−
[533,534]
+
[690,691]
+
[535,536]
+
[537,538]
+
[539–542]
Dysregulated metabolism +
[45,543,544]
+
[545]
+
[544,546]
+
[547]
+
[548,549]
+
[550,551]
0 +
[552]
Immune system evasion 0 +
[553]
+
[554]
+
[555,556]
0 −
[557,558]
+
[559,560]
+
[561,562]
Angiogenesis +
[711]
+/−
[354,563]
+
[564,630,712]
+/−
[565,621]
+
[566]
+
[567,568]
+
[569]
+/−
[570,571]
Tissue invasion and metastasis +
[5,571]
+
[572,573,692]
+
[574]
+/−
[575]
+
[549,576]
−
[577,578]
+/−
[579]
−
[580]
Other characteristics
Tissue interactions in the tumor
microenvironment
+
[581]
+
[582]
+
[583]
+
[584,585]
+
[586]
+
[587,588]
+
[589]
+/−
[587,590–592]
a The cross validation above documents whether the therapeutic targets that are important to block sustained proliferative signaling also block additional hallmarks of cancer as indicated by the cited references. In identifying
these  putative therapeutic targets, + = putative target in sustained proliferative signaling that is shared with other hallmarks (complementary relationship); 0 = putative target not documented in other hallmarks (no relationship);
+/−  = putative target whose inhibition would promote other selected hallmarks (making it controversial as to whether the molecule/pathway should be targeted in cancer at all); − = putative target that promotes sustained
proliferative signaling but inhibits other selected hallmarks (target inhibition has opposite effects, depending upon the hallmark; suggesting a contrary relationship). For example, HIF-1 is activated by mutation, confers resistance
to  apoptosis, supports replicative immortality, dysregulates cell metabolism, stimulates angiogenesis, metastasis, and alters tumor microenvironment. All of these features promote tumorigenesis, suggesting it is a good target
for  therapeutic intervention in multiple steps of tumor pathogenesis.
b The numbers in each box are the references that document whether the putative therapeutic target in each column is also a target for the other hallmarks.
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Table  7
Therapeutic approaches targeting sustained proliferative signaling.
Other cancer hallmarksa Phytochemical approaches
Curcumina Resveratrol Genistein
Genomic instability +
[597,603,635,636] b
+
[657,658,693–695]
+
[674,706]
Tumor-promoting
Inﬂammation
+
[322,593,595,637–639]
+
[347,353,612,613,659–661]
+/−
[397,675–377,707–709]
Evasion of anti-growth
signaling
+
[605,627,640–642]
+
[347,614,662,663]
+/−
[397,678–680]
Resistance to apoptosis +
[347,449,521,537,594,598,600,602,
606–609,618,627,643]
+
[194,344,347,611,614,622,664]
+
[681]
Replicative immortality +
[617,644–646]
+
[665,666]
+
[616,682]
Dysregulated metabolism +
[474,593,617,625,647,648]
+
[6,28,74,76,347,613,667,668,696–700]
+/−
[76,633,683,984]
Immune system evasion +
[76,649]
+/−
[701–705]
+/−
[710]
Angiogenesis +
[474,596,601,619,650]
+/−
[610,665,669,698]
+
[623,685]
Tissue invasion and metastasis +
[594,599,604,629,651–654]
+
[352,615,624,626,670,671]
+
[631,632,686]
Other characteristics
Tissue interactions in the
tumor microenvironment
+
[628,644,655,656]
+
[672,673]
+
[687,688]
a The cross validation above documents whether the compounds that are most likely to be effective against sustained proliferative signaling also block additional hallmarks
of  cancer as indicated by the cited references. In identifying natural compounds most useful for therapeutic intervention, + = compounds that are effective against sustained
proliferative signaling and other hallmarks (complementary relationship); 0 = compound effective against sustained proliferative signaling that are not documented in other
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s  to whether the compound should be used against cancer at all); − = compound
easuring other selected hallmarks (drug has opposite effects; suggesting a contra
b The numbers in each box are the references that document whether the putativ
ood news is that remarkable resources are rapidly accumulating in
he public domain that will help to translate these recent advances
n genomics and bioinformatics to the clinical setting through such
pproaches as the identiﬁcation of biomarkers involved in tumor
roliferation (Fig. 7). The challenge is to train researchers who can
nterpret the molecular data and are able to handle and integrate
assive and diverse datasets. The ability to integrate these data
ypes into comprehensive dynamic models using genetic pathways,
rotein-protein interaction networks, and genetic regulatory net-
orks will ultimately connect changes at the molecular level to
he phenotypic level, with potential clinical outcomes in arresting
umor progression.
3. Conclusions and prospects
Targeting mechanisms involved in uncontrolled cancer cell pro-
iferation will increasingly become the standard of care for cancer
atients, and this review has highlighted some of the “best” targets
n several pathways that regulate proliferation. For example, in pre-
eoplastic tissue the expression of Snail1/2 will need to be blocked
n order to maintain E-cadherin expression and tissue integrity
nd to prevent EMT. Once E-cadherin is lost, and hypoxia devel-
ps, it will be important to block HIF-1 either directly or indirectly
y utilizing inhibitors of Hsp90, topoisomerase, or mTOR. Target-
ng the generation and growth of CSCs will be a major challenge,
ue to the overlap of currently identiﬁed pathways between CSCs
nd SCs. Maintaining CSC dormancy may  prevent reactivation of
isease once the mature tumor cells have been eliminated by con-
entional therapies and remission has been achieved, but it is not
lear how this can be done. Antagonists of Wnt, Hh and MAPK p38
ignaling may  be of some value in this, while increasing C/EBP
xpression, which promotes differentiation, might push CSC into a
herapy sensitive state. In addition to -catenin, there is rationale
o seek antagonists of Notch, HER2/ErbB2 and the IGF-1/IGFR1 sig-
aling pathways, since these are central to cell fate decisions and
re often reactivated in cancer. In the context of the cell cycle, italing promotes but not consistently against other selected hallmarks (controversial
tive against sustained proliferative signaling shown to promote tumorigenesis by
tionship).
pound in each column also targets other hallmarks.
will be important to target cyclin D and cdk4/6. Among hormone
sensitive cancers, ER and AR are prime targets for the continued
development of antagonists. Thus, there are a number of putative
targets in sustained proliferative signaling that may  be considered
for future drug development and evaluation.
Table 6 lists the target molecules and pathways that seem to
be the most important in promoting sustained proliferation and
enabling cells to acquire other hallmarks of cancer. As shown,
there are 10 hallmarks listed, and an eleventh category, “tumor
microenvironment,” which is not a hallmark but is being evalu-
ated here as well. For example, HIF-1 signaling is an important
therapeutic target for all the cancer hallmarks with the proba-
ble exception of evasion of growth suppression and the immune
system evasion. Since HIF-1 promotes survival and growth under
hypoxic conditions, it may  be a therapeutic target in 8 out of the
10 cancer hallmarks where data is reported (which includes sus-
tained proliferative signaling). Thus, it is likely that drugs that
block HIF-1 signaling will be effective against multiple tumor
types in their very early stages. Among other pathways, inhibit-
ing PI3K/Akt signaling would block all of the hallmarks, while
inhibiting Wnt  signaling would block at least 6 of the 10 hall-
marks (Table 6). Since blocking NF-B or Wnt  signaling promote
or suppress replicative immortality, corresponding inhibitors will
have to be evaluated more carefully for each tumor type. Like-
wise, drugs that would block development of some hallmarks
actually promote the growth of androgen and estrogen depen-
dent tumors (Table 6). When considering which hallmarks would
make the best targets for therapeutic intervention, resistance to
apoptosis, dysregulated cell metabolism, evasion of growth sup-
pression, the development of genomic instability, in addition to
sustained proliferative signaling, would rank high. These hall-
marks seem to be sensitive to inhibition from many signaling
pathways, although which pathways are most important remains
to be determined. Importantly, tissue/tumor interactions in the
microenvironment would also be an excellent target for therapeu-
tic intervention.
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To determine which natural compounds are likely to be most
ffective against multiple cancer hallmarks, a literature search was
erformed. Table 7 shows that curcumin, which targets HIF-1, NF-
B, and PI3K/Akt signaling (Table 5), is also active against all of
he cancer hallmarks, as well as the tumor microenvironment.
enistein is effective against at least 6 of the 10 hallmarks while
esveratrol is effective in 8 of 10. However, in some cases the, appro-
riate studies comparing a compound and a particular hallmark
ave not been performed, so that “no relationship” between these
rugs and some of the hallmarks has been reported. In the case of
enistein, it is not clear whether it promotes or inhibits the dysreg-
lation of cell metabolism, evasion of growth suppression, immune
ystem evasion, and tumor promoting inﬂammation. For resvera-
rol, different reports document a positive or negative effect of this
ompound upon immune system evasion and angiogenesis. Impor-
antly, all three of these compounds block the development of
ther hallmarks, which are critical steps in carcinogenesis. Impor-
antly, all of these compounds also appear to be effective against
he tumor microenvironment. Thus, combination therapy with cur-
umin, genistein and resveratrol may  be effective against multiple
argets (and cancer hallmarks) in many tumor types, suggesting
hat they would be very good choices for further clinical develop-
ent and widespread application.
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